Compare SPT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | AVXL |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.6M | 289.1M |
| IPO Year | 2019 | 2013 |
| Metric | SPT | AVXL |
|---|---|---|
| Price | $6.37 | $3.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $11.75 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.4M | 863.0K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $457,547,000.00 | N/A |
| Revenue This Year | $8.86 | N/A |
| Revenue Next Year | $8.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $4.92 | $2.61 |
| 52 Week High | $23.56 | $13.99 |
| Indicator | SPT | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 40.92 |
| Support Level | $6.03 | $2.93 |
| Resistance Level | $7.39 | $3.50 |
| Average True Range (ATR) | 0.42 | 0.18 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 38.01 | 16.33 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.